Skip to main content

Table 3 Management and outcome of infections caused by non-extended-spectrum beta-lactamase (ESBL)- and ESBL-producing Enterobacterales

From: Temporal trends, risk factors and outcomes of infections due to extended-spectrum β-lactamase producing Enterobacterales in Swiss solid organ transplant recipients between 2012 and 2018

  Cases (N = 51) Controls (N = 51) p valuea
Management
Hospital admission if community onset, N (%) 14 (43.8%) 16 (50.0%) 0.99
Length of stay after infection (median, IQR) 18 (8.2–30) 9 (3–24) 0.10
On intensive care after infection onset, N (%) 8 (23.5%) 9 (25.7%) 1.00
 Days on intensive care (median, IQR) 5.5 (4–16) 3 (2–11) 0.38
Infectious diseases consult, N (%) 27 (52.9%) 22 (43.1%) 0.43
 Initially 21 (41.2%) 16 (31.4%) 0.41
 Upon microbiology results 18 (35.3%) 19 (37.3%) 1.00
Antibiotics (30 days after infection), N (%)
 Adequate empiric therapyb 16 (35.6%) 34 (75.6%) < 0.001
 Inadequate BL/BLIc 10 (22.7%) 1 (2.3%) 0.004
 Inadequate ceftriaxone/ceftazidime 2 (4.5%) 0 (0%) 0.15
 Inadequate ciprofloxacin 5 (11.4%) 1 (2.3%) 0.09
 No therapy before day 2 11 (21.5%) 8 (18.2%) 0.44
Outcome
Re-admission, N (%) 15 (29.4%) 14 (27.5%) 1.00
 Due to infection 12 (23.5%) 8 (15.7%) 0.35
Unfavourable outcome within 90 days, N (%) 24 (47.1%) 9 (17.6%) 0.003
 Relapse 20 (39.2%) 5 (9.8%) 0.001
 Graft loss 1 (2.0%) 4 (7.8%) 0.36
 Death 4 (7.8%) 3 (5.9%) 1.00
  1. ESBL extended-spectrum beta-lactamase, IQR interquartile range, BL/BLI beta-lactam/beta-lactamase-inhibitor
  2. aChi-square or Fisher’s exact test for dichotomous variables, as appropriate; Mann–Whitney U for continuous variables
  3. bAdministered within two days after infection diagnosis
  4. cInadequate BL/BLI were all piperacillin/tazobactam except for one case who received amoxicillin/clavulanic acid